Microalbuminuria is more consistent in the presence of cardiovascular risk factors

Journal of Nephrology

Volumn 26, Issue 3, 2013, Pages 580-585

  van der Tol, Arjan ^a   van Biesen, Wim ^a   de Groote, Guy ^b   Verbeke, Paul ^c   Vermeiren, Frans ^c   Eeckhaut, Kathleen ^c   Vanholder, Raymond ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b BARC CRI Laboratories   (Belgium)

^c Adhesia   (Belgium)

Author keywords

Cardiovascular risk factors; General population; Microalbuminuria; Screening for cardiovascular and renal risk

Indexed keywords

ALBUMIN; CREATININE; GLUCOSE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; OBSERVATIONAL STUDY; OCCUPATIONAL HEALTH; PREVALENCE; PROSPECTIVE STUDY; REPRODUCIBILITY; RISK ASSESSMENT; SCREENING TEST; URINE LEVEL; WORKER;

ADULT; ALBUMINURIA; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84878000361     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000194     Document Type: Article

References (30)

1. Romundstad S, Holmen J, Kvenild K, Aakervik O, Hallan H. Clinical relevance of microalbuminuria screening in self-reported non-diabetic/non-hypertensive persons identified in a large health screening-the Nord-Trøndelag Health Study (HUNT), Norway. Clin Nephrol. 2003;59(4):241-251.
2. Hallan SI, Stevens P. Screening for chronic kidney disease: which strategy? J Nephrol. 2010;23(2):147-155.
3. Nielen MM, Schellevis FG, Verheij RA. The usefulness of a free self-test for screening albuminuria in the general population: a cross-sectional survey. BMC Public Health. 2009;9:381.
4. Haynes R, Winearls C. Screening for risk with albuminuria: should we start from here? Nephrol Dial Transplant. 2010;25(11):3463-3465.
5. Bottomley MJ, Kalachik A, Mevada C, Brook MO, James T, Harden PN. Single Estimated Glomerular Filtration Rate and Albuminuria Measurement Substantially Overestimates Prevalence of Chronic Kidney Disease. Nephron Clin Pract. 2010;117(4):c348-c352.
6. Weir MR, Bakris GL. Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol. 2010;31(5):469-470.
7. Fink HA, Ishani A, Taylor BC, et al. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the u.s. Preventive services task force and for an american college of physicians clinical practice guideline. Ann Intern Med. 2012;156(8):570-581.
8. Mogensen CE, Vestbo E, Poulsen PL, et al. Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care. 1995;18(4):572-581.
9. van der Tol A, Van Biesen W, Van Laecke S, et al. Statin Use and the Presence of Microalbuminuria. Results from the ERICABEL Trial: A Non-Interventional Epidemiological Cohort Study. PloS One. 2012;7(2):e31639.
10. Romundstad S, Holmen J, Kvenild K, Hallan H, Ellekjaer H. Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trøndelag Health Study (HUNT), Norway. Am J Kidney Dis. 2003;42(3):466-473.
11. Wang TJ, Evans JC, Meigs JB, et al. Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation. 2005;111(11):1370-1376.
12. Halimi JM, Bonnet F, Lange C, Balkau B, Tichet J, Marre M. Urinary albumin excretion is a risk factor for diabetes mellitus in men, independently of initial metabolic profile and devel opment of insulin resistance. The DESIR Study. J Hypertens. 2008;26(11):2198-2206.
13. Yuyun MF, Khaw KT, Luben R, et al. Microalbuminuria, cardiovascular risk factors and cardiovascular morbidity in a British population: the EPIC-Norfolk population-based study. Eur J Cardiovasc Prev Rehabil. 2004;11(3):207-213.
14. van der Tol A, Van Biesen W, Verbeke F, et al. Towards a rational screening strategy for albuminuria: results from the unreferred renal insufficiency trial. PloS One. 2010;5(10):e13328.
15. Warram JH, Gearin G, Laffel L, Krolewski AS. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol. 1996;7(6):930-937.
16. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247-254.
17. Cleeman JI, Grundy SM, Becker D, et al. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
18. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-1847.
19. Van der Tol A, Van Biesen W, De Groote G, et al. Mislabeling Cardiovascular Risk by One Single Measurement of Microalbuminuria. Acta Clin Belg. 2011;66(2):171.
20. Degli Esposti L, Saragoni S, Buda S, et al. Awareness of albuminuria in an Italian population-based cohort of patients treated with hypoglycemic drugs. J Nephrol. 2012;25(3):325-331.
21. Uchida J, Machida Y, Iwai T, et al. Low-grade albuminuria reduction with angiotensin II type 1 receptor blocker in renal transplant recipients. J Nephrol. 2011;24(4):515-521.
22. Ozyilmaz A, Bakker SJ, de Zeeuw D, de Jong PE, Gansevoort RT. Selection on albuminuria enhances the efficacy of screening for cardiovascular risk factors. Nephrol Dial Transplant. 2010;25(11):3560-3568.
23. van der Velde M, Halbesma N, de Charro FT, et al. Screening for albuminuria identifies individuals at increased renal risk. J Am Soc Nephrol. 2009;20(4):852-862.
24. Hillege HL, Fidler V, Diercks GFH, et al. Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106(14):1777-1782.
25. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000; 355(9200):253-259.
26. Keane WF, Zhang Z, Lyle PA, et al. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol. 2006;1(4): 761-767.
27. Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110(18):2809-2816.
28. Brantsma AH, Bakker SJ, Hillege HL, de Zeeuw D, de Jong PE, Gansevoort RT. Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes. Diabetes Care. 2005; 28(10):2525-2530.
29. Halimi JM, Forhan A, Balkau B, et al. D.E.S.I.R. Study Group. Is microalbuminuria an integrated risk marker for cardiovascular disease and insulin resistance in both men and women? J Cardiovasc Risk. 2001;8(3):139-146.
30. Verhave JC, Hillege HL, Burgerhof JGM, Navis G, de Zeeuw D, de Jong PE; PREVEND Study Group. Cardiovascular risk factors are differently associated with urinary albumin excretion in men and women. J Am Soc Nephrol. 2003;14(5):1330-1335.